Market
Series D round oversubscribed, bringing total funding to $430 million Proceeds to support commercialization of FDA-cleared implant and clinical expansion

Precision Neuroscience, a company specializing in brain-computer interfaces (BCIs), raised $250 million in a Series D round.
The round closed oversubscribed, according to Fierce Biotech on the 28th (local time). The financing brings Precision’s total funding to $430 million.
Precision said it has built the largest clinical network in the BCI field, conducting more than 100 patient procedures at 18 medical institutions.
In March 2025, the company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Layer 7 cortical interface, which records, monitors and stimulates electrical activity in the brain. The device can be temporarily implanted for up to 30 days and was co-developed with Medtronic.
Recent research found that BCI training using feedback on electrical activity in the brain may help improve cognitive function in patients with Parkinson’s disease, multiple sclerosis, dementia and traumatic brain injury.
Michael Mager, Precision’s co-founder and CEO, said in a statement, “The next phase of BCI will not be defined by technology alone. We have built the clinical network, regulatory position and manufacturing base needed for leadership in this field, and we are putting safety at the center of product design.”
The proceeds will be used to expand clinical programs, advance Layer 7 through the next stage of FDA review and build the infrastructure needed for commercialization.
The round was co-led by Pershing Square, the Ackman Oxman Institute and a life sciences investment fund. Duquesne Family Office, B Capital, ARK Invest, Inverse, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital also participated.
Meanwhile, Chinese medical authorities approved for commercial use in March what they described as the world’s first BCI device to help patients with spinal cord injuries regain some hand movement. Developed by Shanghai-based Neurocle Technologies, the device connects an implantable electroencephalography (EEG) electrode to a pneumatic robotic glove that can grasp objects.

Biobook Team
biobookmedia@biobook.co.kr
Orient Bio Expands Domestic Supply of SPF Rabbits, but Reversal of Chronic Losses Remains Elusive

Celltrion’s Third-Quarter Operating Profit Surges 69% to 510 Billion Won

ViOL Medical Wins Thai Approval for HIFU Device, Laying Groundwork for Consumables Revenue

SCD Pharm’s glaucoma drug Latast reaches 11% market share, supplied back to originator

Alteogen’s ALT-B4 Infringes Halozyme Patent in Europe; Keytruda SC Sales Banned in 8 Countries

Immunology Drug Developer TrexBio Prices $117 Million IPO
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th